The PAT is up 11% quarter-on-quarter from Rs 252 crore in Q3FY26 while the topline was 2% higher sequentially versus Rs 1,778 crore in the October-December quarter of FY26.
The Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) in the quarter under review stood at Rs 523 crore, rising 10% over Rs 477 crore in Q4FY25. It was 8% higher sequentially.
Company’s gross margins stood at 61.4%, up from 54.5% in the year ago period. It rose 690 bps YoY and 50 bps QoQ.
The R & D spends were reported at Rs 76 crore which is 4.2% of revenues.
The company’s board of directors approved the payment of second interim dividend of Rs 1.20 for the financial year 2025-26 and has fixed May 8, 2026 as the record date for determining the eligibility of the shareholders. The Dividend amount will be paid on or after May 20, 2026.
The net profit for FY26 stood at Rs 889 crore, which increased 148% from Rs 358 crore in FY25. The revenues in FY26 stood at Rs 6,813 crore, which increased 23% driven by continued strong growth across both CDMO and Affordable Medicine (Generics) division.The full-year EBITDA stood at Rs 1,826 crore, which increased by 64% YoY.
The company in its filing to the exchanges said strong OCF (operating cash flow) was due to higher EBITDA and improved net working capital. The net debt to EBITDA reduction was largely in line and better operating leverage drove ROCE while CAPEX momentum continued.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)